

Meet The Professor: Optimizing the Management of Ovarian Cancer —
Part 2 of a 5-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What was the duration of treatment with olaparib and with niraparib in the Phase III SOLO-1 and PRIMA trials, respectively, evaluating those agents as maintenance therapy after debulking surgery and first-line platinum-based chemotherapy?**
 - a. Two years for both
 - b. Three years for both
 - c. Two years for olaparib, 3 years for niraparib**
 - d. Two years for niraparib, 3 years for olaparib
- 2. In the Phase III PAOLA-1 study the addition of olaparib to bevacizumab as first-line maintenance therapy for advanced ovarian cancer resulted in an improvement in progression-free survival (PFS) in which of the following subgroups?**
 - a. Patients with tumor BRCA mutations
 - b. Patients without tumor BRCA mutations
 - c. Patients with homologous recombination deficiency (HRD)-positive tumors, including those with BRCA mutations
 - d. Patients with HRD-positive tumors without BRCA mutations
 - e. All of the above subgroups**
- 3. The ongoing Phase III DUO-O trial is evaluating durvalumab with platinum-based chemotherapy and bevacizumab followed by which of the following maintenance regimens for patients with newly diagnosed advanced ovarian cancer?**
 - a. Durvalumab
 - b. Bevacizumab/niraparib
 - c. Durvalumab/ramucirumab/rucaparib
 - d. Durvalumab/bevacizumab/olaparib**
- 4. Which of the following patients with advanced ovarian cancer derived the greatest PFS benefit in the Phase II OVARIO trial evaluating niraparib/bevacizumab after first-line bevacizumab/platinum chemotherapy?**
 - a. Those with homologous recombination-deficient (HRd) tumors**
 - b. Those with homologous recombination-proficient (HRp) tumors
 - c. Outcomes were equivalent for patients with HRd and HRp tumors
- 5. Which of the following best describes the target of the novel antibody-drug conjugate upifitamab rilsodotin currently under investigation for patients with ovarian cancer?**
 - a. Folate receptor alpha
 - b. NaPi2b**
 - c. Tissue factor
 - d. TROP2